Human Microbiome Clinical Trial
— IsoMicOfficial title:
Isolation and Characterization of Fecal/Oral/Skin/Nasal/Throat Microbial Species From a Diverse Cohort of Healthy Adults
NCT number | NCT05150184 |
Other study ID # | NH10009 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | November 17, 2021 |
Est. completion date | May 23, 2023 |
Verified date | September 2023 |
Source | Danisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Isolation and characterization of fecal/oral/skin/nasal/throat microbial species from a diverse cohort of healthy adults.
Status | Completed |
Enrollment | 52 |
Est. completion date | May 23, 2023 |
Est. primary completion date | March 23, 2023 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: 1. Voluntary, written, informed consent to participate in the study 2. Agreement to comply with the protocol and study restrictions 3. Healthy females and males of age 18 to 50 years (inclusive) 4. Participants recognize themselves as white or American Indian or Alaska Native or Asian or Black / African American or Native Hawaiian or Other Pacific Islander or Hispanic and Latinos or Multiracial. Participant numbers are limited to a maximum of 10 (males and females) from each group. 5. Participants consume > 4 portions of fruits and vegetables per day and who agree to maintain their usual dietary habits, their usual exercise habits, hygienic habits and their lifestyle in general throughout the trial period 6. Females of child-bearing potential who agree to use medically approved methods of birth control 7. Ability of the participant (in the investigator's opinion) to comprehend the full nature and purpose of the study 8. BMI between 18.5-25. Exclusion Criteria: 1. Participation in a clinical trial with an investigational product or drug within 60 days prior to screening. 2. Likeliness to be noncompliant with the protocol, or to be unsuitable to the study as judged by the study staff for any reason. 3. Planned major changes in life style (i.e. diet, dieting, exercise level, travelling). 4. History of diagnosed eating disorder (anorexia, bulimia). 5. Consumption of fast food > 3 times/week. Where fast food is referred to high carbohydrate and fat rich diet. 6. History of drug (> 2 times per week) during last 2 years or alcohol abuse (> 08 portions per week for females and 15 portions/week for males, or >3 portions/day) during the last 3 months. 7. Pregnant or breastfeeding women; women planning to become pregnant during the study. 8. Clinically significant underlying systemic illness that may preclude the participant's ability to complete the trial or that may affect the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness, coronary heart disease/cardiovascular disease or artificial heart valve, HIV, STD, AIDS, hepatitis and autoimmune diseases e.g. MS-disease, thyroid diseases) 9. Use of prescription anti-obesity drugs, temporary or irregular medication for diabetes, dyslipidemia or hypertension, non-steroidal anti-inflammatory drugs, corticosteroids, or equivalent immunomodulatory drugs, immunosuppression or ongoing therapy causing immunosuppression and ongoing or recent (last 3 months) antibiotic treatment. 10. Diagnosed or suspected organic gastrointestinal disease (e.g. colitis, Crohn's disease, celiac disease, recurrent diverticulitis) or non-organic disease (e.g. IBS), or functional constipation, during the last year. 11. Colonoscopy within 3 months before screening 12. Colon cleansing within 3 months before screening. 13. Gastrointestinal infection within 6 months before screening 14. Active or recent (last 3 months) participation in a weight loss program including weight change (increase or loss) of 3 kg during the past three months. History of bariatric surgery. 15. History of gingivitis, periodontitis, or any oral disease during last 6 months. 16. History of smoking or tobacco use in any form and/or electronic cigarette during the last 6 months. 17. History of skin diseases (e.g. atopic dermatitis (Eczema), hives, dermatitis, psoriasis, or rashes) during the last 6 months. 18. History of SARS CoV-2 infection. 19. Participants under administrative or legal supervision. 20. Other reasons that, in the opinion of the Investigator, make the participant unsuitable for enrollment |
Country | Name | City | State |
---|---|---|---|
United States | Reprocell | Beltsville | Maryland |
Lead Sponsor | Collaborator |
---|---|
Danisco | Reprocell Inc, Serologix |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Analysis of microbiomes from various body sites | Analysis of microbiomes from various body sites | within 2 weeks of collection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05560087 -
Association of PeRiODontal Disease and gUt Microbiome With Coronary artEry Disease (PRODUCE Study)
|
||
Completed |
NCT04222699 -
Cultures Before and After Decolonization in Community Dwelling Adults With Current S. Aureus Colonization
|
Phase 4 | |
Completed |
NCT02392182 -
Lung HIV Microbiome Project (Michigan Site)
|
N/A | |
Completed |
NCT04597502 -
The Effects of Terminalia Chebula Fruit Extract on the Gut Microbiome and Skin Biophysical Properties
|
N/A | |
Completed |
NCT04596722 -
Oral Pomegranate Extract on the Microbiome and Skin Biophysical Properties
|
N/A | |
Completed |
NCT02731976 -
Microbiome Composition Changes on 4 Week Gluten-free Diet Challenge
|
N/A | |
Recruiting |
NCT03942159 -
Modification of the Human Colon and Oral Microbiome by Allogenic HSCT
|
||
Completed |
NCT04335526 -
A Clinical Study to Assess the Effect of Change of Bile Acid on the PD and Safety of Metformin and Microbiome Profiles
|
Phase 1 | |
Completed |
NCT03668015 -
Xylitol and Sorbitol Effects on the Oral Microbiome
|
N/A | |
Completed |
NCT03157687 -
Detection of Luminal and Mucosa-associated Microbiome in Healthy Controls vs. Local and Systemic Inflammation
|
||
Not yet recruiting |
NCT04841694 -
Oral Probiotics on the Shift in Gut Microbiome and Skin Carotenoid Levels
|
N/A | |
Enrolling by invitation |
NCT03231332 -
Effects of H.Pylori Eradication on Microbiome
|
Phase 4 | |
Completed |
NCT03181269 -
Human Milk and Infant Intestinal Microbiome Study
|
N/A | |
Completed |
NCT03543605 -
Clinical/Microbiological Impact of a Specific Antimicrobial Stewardship Program for Nursing Homes
|
N/A | |
Completed |
NCT01496898 -
Changes in Vaginal, Cervical and Uterine Microflora With Levonorgestrel Intrauterine Device Placement
|
N/A | |
Terminated |
NCT03907501 -
Effects of Triphala and VSL#3 Probiotic Supplementation on Stool Microbiome Profiles and Inflammation
|
N/A | |
Completed |
NCT03809260 -
A Clinical Trial for Analysis of Intestinal Microbiome Affecting PK, PD, and Safety of Metformin
|
N/A | |
Completed |
NCT04218799 -
Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans
|
Phase 4 | |
Completed |
NCT03581812 -
Snack Foods and Their Impact on Gastrointestinal Microbiology, Function and Symptoms
|
N/A | |
Withdrawn |
NCT02407184 -
Potential Restoration of the Infant Microbiome
|
N/A |